Marlton Partners Comments on 180 Degree Capital Corp. and Mount Logan Capital Inc. Business Combination

Stock Information for Lineage Cell Therapeutics, Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lineage Cell Therapeutics, Inc.

Mount Logan Capital Inc. Begins Trading on Nasdaq Under "MLCI"
Mount Logan Capital Inc. and 180 Degree Capital Corp. Close Strategic Business Combination
180 Degree Capital Announces Results of Special Meeting of Shareholders to Approve the Proposed Business Combination With Mount Logan Capital Inc.
180 Degree Capital Corp. and Mount Logan Capital Inc. Announce Revised Terms of Business Combination in Response to Constructive Conversations With Shareholders
Marlton Partners Files Preliminary Proxy Statement Related to Election of Directors for the 180 Degree Capital Board of Directors
180 Degree Capital Corp. and Mount Logan Capital Inc. Provide Update on Proposed Business Combination
Mount Logan Capital Inc. Announces Second Quarter 2025 Financial Results
A Leading Independent Proxy Advisory Firm, Glass Lewis, Recommends Shareholders Vote in Favor of the Proposed Merger Between 180 Degree Capital Corp. and Mount Logan Capital Inc.

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.